Abstract: The present invention provides a magnetic biochar-quaternary phosphonium salt bactericidal material, a preparation method therefor and usage thereof, and belongs to the field of water treatment. The preparation method comprises: 1) using corn straw biochar as a precursor to prepare magnetic biochar by a co-precipitation method; and 2) adding the magnetic biochar into deionized water, then adding a quaternary phosphonium salt, performing the magnetic stir at room temperature, raising the temperature after sufficient impregnation, carrying out a hydrothermal reaction, and then cooling to the room temperature to obtain the bactericidal material. The temperature is raised to 60° C.˜70° C.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: The disclosure relates to oral delivery compositions that transition from a flowable state to a hardened or semi-hardened state. The flowable hardening composition may be delivered to oral tissues, including teeth and/or gums, directly or using a barrier strip or a tray-like device. Such compositions may be configured as a multi-part system wherein reactive materials (e.g., catalyst and reactive resins) are kept separate until use. Dispersion of the agents in a viscous carrier within the hardened composition enables a gradual release the desired agent(s) to reduce or eliminate sensitivity that may be caused by certain agents (e.g., dental whitening agents). The hardened delivery composition may include a reverse image of the oral tissue, allowing it to be removed and replaced multiple times during a single use, giving users more flexibility during treatment.

Abstract: Ready-to-use (RTU) Sodium Phosphates solutions for phosphorus replacement therapy are presented that include Sodium phosphate with/without sodium chloride at a fixed volume with 1.5 to 15 mmol/100 mL phosphorus, no more than 20 mEq/100 mL Sodium and less than 50 mcg/L aluminum.

Abstract: The present invention relates to antibacterial carbon dots, having aminoguanidine functionality on their outermost surface. The invention further relates to the synthesis of said antibacterial carbon dots, and to the uses of these carbon dots for inhibiting a biofilm formation in the presence of said carbon dots and as fluorescent labeling markers for specific bacteria.

Abstract: Biodegradable resin particles including a polyhydroxy alkanoate. In the biodegradable resin particles, an amount of a Ca component present in the particles is 10 to 10,000 ppm, the biodegradable resin particles have a volume average particle diameter of 2 to 50 ?m, the biodegradable resin particles have a BET specific surface area of 0.8 to 10 m2/g, and the biodegradable resin particles have a linseed oil absorption of 50 to 300 ml/100 g. The resin particles of the present invention can be suitably used by being included in an external preparation, such as a cosmetic or a quasi-drug.

Abstract: Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Abstract: Zinc oxide particles are prepared as a dry powder through a vapor phase formed by a plasma process, or by introducing defects into stoichiometric zinc oxide particles in a liquid carrier through mechanical stress. The zinc oxide has an O:Zn ratio of at least 0.99, an average particle size of 10 to 300 nm, and a sufficient concentration of oxygen vacancies and zinc vacancies to give a dispersion of the particles in C12-C15 alkyl benzoate an orange to tan color corresponding to a ?E value of at least 15 in a Dispersion Color Test. The particles contain no aggregates and have no detectable particles 500 nm or larger, on a number-weighted basis.

Abstract: The disclosure relates to methods of making an osteoconductive polymer article for use as an orthopedic implant comprises steps of forming an article from a biocompatible, non-biodegradable polymer, the article comprising a non-flat surface with roughness Ra of at least 5 ?m; providing a dispersion of bioactive ceramic particles of particle size at most 10 ?m in a first solvent comprising a solvent for the polymer; coating at least the non-flat surface with the dispersion in at least one step; and rinsing the coated article with a second solvent being a non-solvent for the polymer to substantially remove the first solvent.

Abstract: The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to prevent viral infections caused be RNA viruses that have a lipid capcid. An agent for prevention viral infections comprises viral material from RNA viruses that have a lipid capcid and stabilized colloidal selenium at a 1:1 ratio. The viral material from RNA viruses has titres of 6.0-8.0 lg TCD50/ml. To obtain colloidal selenium having particle sizes from 10 to 15 nm the colloidal selenium is stabilized with polyethylene glycol, and for colloidal selenium having particle sizes from 20 to 40 nm, the colloidal selenium is stabilized with cysteine.

Abstract: The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

Abstract: The technology relates to a 3D printed hydrogel formed from a maleimide containing polymer cross-linked using a bis-thiol containing cross-linking agent having at least two thiol functional groups, processes for preparing the 3D printed hydrogel, and uses thereof.

Abstract: The present disclosure provides a method for extracting Gymnadenia conopsea(L.)R.Br., which includes the following steps: (1) the root tuber of Gymnadenia conopsea(L.)R.Br. is soaked in water so that it can be fully infiltrated until having been taken as a sample, no white core is observed; (2) the root tuber of Gymnadenia conopsea(L.)R.Br. is ultrafinely comminuted by wet method to obtain a dispersion slurry; (3) additional water is supplemented into the dispersion slurry to obtain diluted dispersion followed by heating and adding neutral protease, and then extraction is carried out through circulation and homogenization by the homogenization pump to obtain extracted material fluid; (4) heat preservation and enzyme inactivation; (5) coarse filtration to obtain a coarse filtrate; and (6) fine filtration to obtain a fine filtrate. The disclosure also provides a related extract of Gymnadenia conopsea(L)R.Br.

Abstract: Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use.

Abstract: Synthesis of a compound 2-oxo-2-({2-[(phenylcarbamoyl)oxy]ethyl}amino)ethyl phenylcarbamate and its use as an insecticidal agent.

Abstract: This cosmetic product has extensibility and imparts use feels such as silkiness and smoothness, and further demonstrates excellent soft focus effects, and contains: (A) spherical organopolysiloxane particles of which 90% by mole or more are constituted from organosilsesquioxane units and which have a volume average particle size of 0.1 to 30 ?m and an average refractive index of 1.44 to 1.57, and; (B) an oil agent; and one or more selected from (C) a silicone crosslinked product and (D) a silicon resin coating silicon rubber powder.

Abstract: Pituitary tumors may be reduced in size by administration of relacorilant. Pituitary tumors include, without limitation, non-secreting tumors, hormone-secreting tumors, adenomas, and carcinomas. Relacorilant administration may be effective to reduce hormone secretion from a hormone-secreting pituitary tumor, e.g., to reduce adrenocorticotrophic hormone (ACTH) secretion. A pituitary tumor may be imaged before and/or after relacorilant administration. Relacorilant may be administered independent of surgery, and before, during, or after surgery to treat a pituitary tumor. Relacorilant may aid or improve surgical outcomes, and may reduce the size or growth of pituitary tumor tissue before surgery, and any tumor tissue remaining following surgical treatment. Relacorilant may be orally administered for the treatment of pituitary tumors. Relacorilant may be orally administered to a fasted patient, or to a fed patient.

Abstract: A balloon catheter for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen; the balloon catheter comprising: An elongated balloon; a coating layer overlying an exterior surface of the balloon wherein the coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent; and a length-control mechanism (600) which stretches and elongates the balloon during deflation, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Abstract: The present specification describes a biocompatible hemostatic composition and a biocompatible tissue sealant, which when used in combination provides a safe and effective method of achieving hemostasis. The biocompatible composition and sealant may be applied either on a surface of the patient's body, or inside the body cavity. The combination may be used to control bleeding from external wounds and internal injuries, as well as to minimize bleeding during surgical procedures.